The original success of the copyright undeniably revolutionized the drug landscape, but placing funds in companies primarily reliant on unbranded versions presents a uncertain picture. Despite early profits were significant, the end of patents and the appearance of discounted alternatives have diminished market share. Consequently, a thorough evalu